103 results about "Diastolic function" patented technology

Devices and methods are described herein which are directed to the treatment of a patient's heart having, or one which is susceptible to heart failure, to improve diastolic function.

Systems and methods for noninvasive assessment of cardiac tissue properties and cardiac parameters using ultrasound techniques are disclosed. Determinations of myocardial tissue stiffness, tension, strain, strain rate, and the like, may be used to assess myocardial contractility, myocardial ischemia and infarction, ventricular filling and atrial pressures, and diastolic functions. Non-invasive systems in which acoustic techniques, such as ultrasound, are employed to acquire data relating to intrinsic tissue displacements are disclosed. Non-invasive systems in which ultrasound techniques are used to acoustically stimulate or palpate target cardiac tissue, or induce a response at a cardiac tissue site that relates to cardiac tissue properties and / or cardiac parameters are also disclosed.

An elastic structure is introduced percutaneously into the left ventricle and attached to the walls of the ventricle. Over time the structure bonds firmly to the walls via scar tissue formation. The structure helps the ventricle expand and fill with blood during the diastolic period while having little affect on systolic performance. The structure also strengthens the ventricular walls and limits the effects of congestive heart failure, as the maximum expansion of the support structure is limited by flexible or elastic members.

The present invention provides a system for improving diastolic function of the heart comprising elastic elements and attachment elements, wherein said elastic elements and said attachment elements are configured such that they are capable of being interconnected to form a chain formed of an alternating series of said elastic elements and said attachment elements, and wherein said attachment elements are adapted to be anchored in the wall of the heart and with option for drug delivery to the wall of the heart. The invention further provides devices, methods and kits, for mounting the ventricular function assisting device of the invention.

A compound having the structureuseful for treatment or prevention of cardiovascular diseases, endothelial dysfunction, diastolic dysfunction, atherosclerosis, hypertension, angina pectoris, thromboses, restenoses, myocardial infarction, strokes, cardiac insufficiency, pulmonary hypertonia, erectile dysfunction, asthma bronchiale, chronic kidney insufficiency, diabetes, or cirrhosis of the liver in a human or animal patient.

A system for improving cardiac function is provided. A foldable and expandable frame having at least one anchoring formation is attached to an elongate manipulator and placed in a catheter tube while folded. The tube is inserted into a left ventricle of a heart where the frame is ejected from the tube and expands in the left ventricle. Movements of the elongate manipulator cause the anchor to penetrate the heart muscle and the elongate manipulator to release the frame. The installed frame minimizes the effects of an akinetic portion of the heart forming an aneurysmic bulge. Devices and methods are described herein which are directed to the treatment of a patient's heart having, or one which is susceptible to heart failure, to improve diastolic function.

A system and method for cardiac resynchronization therapy in which pacing control parameters are automatically adjusted by comparison of local electrograms acquired by a cardiac implantable electrical device with a model of cardiac electrical activity derived from surface-lead electrocardiograph measurements under baseline and paced conditions is provided. The adjusted pacing control parameters guarantee substantially maximum evidence of ventricular activation wavefront fusion while reducing the risk of compromising diastolic function. Atrioventricular intervals (AVIs] are measured and utilized to constrain the adjustment of pacing control parameters such that diastolic dysfunctions are not induced in the patient's heart.

The present invention provides an in vivo device for improving diastolic function of the heart, comprising: at least one elastic component that may be operatively connected to the external surface of the left or right ventricle of the heart by means of connecting elements, wherein said elastic component comprises essentially longitudinal members arranged such that the lateral separation therebetween may be increased or decreased in response to elastic deformation of said elastic component, and wherein said essentially longitudinal members are arranged such that said elastic component is curved in both the vertical and horizontal planes, such that its inner surface may be adapted to the curvature of the external ventricular surface of the heart, such that said elastic component is capable of exerting both radially outward expansive and tangentially-directed forces on the external surface of the cardiac ventricle.

A compound having the structureuseful for treatment or prevention of cardiovascular diseases, endothelial dysfunction, diastolic dysfunction, atherosclerosis, hypertension, angina pectoris, thromboses, restenoses, myocardial infarction, strokes, cardiac insufficiency, pulmonary hypertonia, erectile dysfunction, asthma bronchiale, chronic kidney insufficiency, diabetes, or cirrhosis of the liver in a human or animal patient.

In a method of noninvasive measurement of parameters of diastolic function of left ventricle and automated evaluation of the measured profile at rest and with exercise, a patient performs an isometric exercise. An external pressure sensor and heart sounds microphone are applied in a non-invasive manner on the thoracic wall to obtain a left ventricular pressure mirroring curve (pressocardiogram) and simultaneously the heart sounds (phonocardiogram). An external unit determines and calculates characteristic diastolic parameters derived from the pressocardiographic curve and phonocardiogram at rest, during and after exercise, converts each said pressocardiogram into a digital waveform in the time domain, and automatically categorizes the mentioned characteristic parameters based on exact categorization criteria for defining several differentialforms of diastolic dysfunction of left ventricle in human beings.

A system for improving cardiac function is provided. A foldable and expandable frame having at least one anchoring formation is attached to an elongate manipulator and placed in a catheter tube while folded. The tube is inserted into a left ventricle of a heart where the frame is ejected from the tube and expands in the left ventricle. Movements of the elongate manipulator cause the anchor to penetrate the heart muscle and the elongate manipulator to release the frame. The installed frame minimizes the effects of an akinetic portion of the heart forming an aneurysmic bulge. Devices and methods are described herein which are directed to the treatment of a patient's heart having, or one which is susceptible to heart failure, to improve diastolic function.

Disclosed are δ-amino-γ-hydroxy-ω-aryl-alkanoic acid amide compounds of formula (I)and the salts thereof, having renin-inhibiting properties. Also disclosed are pharmaceutical compositions comprising these compounds and methods of administering them for the treatment of hypertension, atherosclerosis, unstable coronary syndrome, congestive heart failure, cardiac hypertrophy, cardiac fibrosis, cardiomyopathy postinfarction, unstable coronary syndrome, diastolic dysfunction, chronic kidney disease, hepatic fibrosis, complications resulting from diabetes, such as nephropathy, vasculopathy and neuropathy, diseases of the coronary vessels, restenosis following angioplasty, raised intra-ocular pressure, glaucoma, abnormal vascular growth, hyperaldosteronism, cognitive impairment, alzheimers, dementia, anxiety states and cognitive disorders.

Methods for determining indicators of left ventricular diastolic function are disclosed. The indicators may include the left ventricular isovolumetric relaxation time and the negative slope of a left atrial “V” wave.

Devices and methods are described herein which are directed to the treatment of a patient's heart having, or one which is susceptible to heart failure, to improve diastolic function.

The present invention is primarily directed towards an anatomically-compatible and physiologically-compatible in vivo device for improving diastolic function of either the left or right ventricle of the heart, wherein said device comprises at least one elastic component in the form of a lattice capable of being arranged in a curved conformation such that one surface of said lattice may be adapted to the curvature of the external ventricular surface of the heart, or a portion thereof, and wherein said at least one elastic component is capable of being operatively connected to the external ventricular surface of the heart by means of one or more connecting elements.

Methods and related apparatus and systems for determining a load-independent index of diastolic function in the heart are described.

An elastic structure is introduced percutaneously into the left ventricle and attached to the walls of the ventricle. Over time the structure bonds firmly to the walls via scar tissue formation. The structure helps the ventricle expand and fill with blood during the diastolic period while having little affect on systolic performance. The structure also strengthens the ventricular walls and limits the effects of congestive heart failure, as the maximum expansion of the support structure is limited by flexible or elastic members.

Heart failure with preserved ejection fraction (HFpEF) is a disease condition characterized by heart failure (HF) signs and symptoms, but with normal or near normal left ventricular ejection fraction (LVEF) and is not responsive to standard therapy for treatment of HF. Described herein are compositions and methods related to use of cardiosphere derived cells (CDCs) and their exosomes to improve left ventricular structure, function and overall outcome. Administration of CDCs led to improved LV relaxation, lower LV end-diastolic pressure, decreased lung congestion and enhanced survival. Lower risk of arrhythmias in HFpEF was also observed following CDC administration. Improvement of diastolic dysfunction following administration of CDC-derived exosomes was observed, along with decreased mortality. In view of these salutary effects, CDCs and CDC-derived exosomes are beneficial in the treatment of HFpEF.

Devices and methods for detecting heart failure (HF) events or identifying patient at elevated risk of developing future HF events are described. A medical device can detect contextual condition associated with a patient, such as an environmental context or a physiologic context, sense a heart sound signal, and perform multiple measurements of heart sound features in response to the detected patient contextual condition meeting specified criterion. The contextual condition includes information correlating to or indicative of a change in metabolic demand of a patient. The medical device can use the physiologic signals to calculate one or more signal metrics indicative of diastolic function of the heart such as a trend of the heart sound features. The medical device can use the signal metrics to detect an HF event or to predict the likelihood of the patient later developing an HF event.

The present invention provides an anatomically-compatible and physiologically-compatible in vivo device for improving diastolic function of either the left or right ventricle of the heart, comprising at least one air-impermeable sheet that is capable of being operatively connected to the external ventricular surface of the heart using one or more connecting elements, such that said at least one air-impermeable sheet is capable of creating a sub-atmospheric pressure within said closed empty space as a consequence of changes in the volume of said space during the course of the cardiac cycle, thereby exerting an outward and normally directed force on the external ventricular surface of the heart.

Bioactive implant for myocardial regeneration and ventricular chamber support including an elastomeric microporous membrane. The elastomeric microporous membrane being at least one non-degradable polymer and at least one partially degradable polymer. The non-degradable polymer is selected from polyethylacrylate and polyethylacrylate copolymerized with a hydroxyethylacrylate comonomer. The partially degradable polymer is selected from caprolactone 2-(methacryloyloxy)ethyl ester and caprolactone 2-(methacryloyloxy)ethyl ester copolymerized with ethylacrylate. The elastomeric microporous membrane further includes a nanofiber hydrogel, and cells. The bioactive implant, having one or two helical loops, contributes to the restauration of the heart conical shape. Cardiac wrapping by ventricular support bioprostheses of the present invention, having reinforcement bands spatially distributed as helicoids, recovers the sequential contraction of the myocardium resulting in the successive shortening and lengthening of the ventricles, therefore improving the ejection (systolic function) and suction of blood (diastolic function).

The invention relates to the atrial contractility-increasing effect of Kv1.5 blockers, especially phenylcarboxamides of the formulae Ia or Ib or pharmaceutically acceptable salts thereof, for treating reduced atrial contractility and heart failure, especially heart failure caused by diastolic dysfunction.

The invention provides a method of treating diastolic dysfunction, e.g., diastolic dysfunction with preserved ejection fraction, in a subject. The method comprises administering to the subject in an amount effective to treat the diastolic dysfunction a cardiac metabolic modifier, as described herein. In some embodiments, the diastolic dysfunction is characterized by (i) a lack of increased late INa in cardiomyocytes, (ii) an increase in myofilament calcium sensitivity, or (iii) a combination thereof. In some embodiments, the subject does not suffer from a cardiac injury or a structural heart disease, as described herein. Further provided are a method of treating heart failure with preserved ejection fraction in a subject, a method of treating acute decompensated heart failure, a method of modulating myofilament calcium sensitivity in a subject, and a method of treating a condition associated with or caused by increased myofilament calcium sensitivity.